11:36 AM
 | 
Aug 23, 2018
 |  BC Innovations  |  Emerging Company Profile

Bugs on film

How Scioto is using biofilm formulation to boost colonization of gut probiotics

Microbiome company Scioto Biosciences Inc. is turning a longstanding enemy of antibiotics developers -- biofilms -- into a delivery vehicle for probiotics.

The company expects its lead candidate SB-121, an orally delivered biofilm formulation of Lactobacillus reuteri, to be useful across a swath of diseases where patients are at risk of developing intestinal inflammation and leakage. Its lead indication is necrotizing enterocolitis, a rare and sometimes fatal disease that occurs in premature babies with low birth weights.

Bacterial pathogens are notorious for secreting biofilms -- sticky extracellular matrices -- that help the bugs adhere to each other and which form a barrier to immune cells and antibiotics, thereby promoting persistent infection.

Scioto is co-opting that function to achieve persistent colonization of orally-delivered therapeutic bacteria in the gut.

The company’s platform is built around porous dextran...

Read the full 653 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >